Seeking Alpha

BMRN
  BioMarin Pharmaceutical Inc. - NASDAQ

9/22/2014, 4:59 AM ET
  • freefdawatchlist | Send Message 5 Nov 2012

    http://bit.ly/RNQTMf Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40.
    Reply
      BMRN vs. ETF Alternatives
      Company Description
      Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.
      Sector: Healthcare
      Industry: Biotechnology
      Country: United States